Denileukin Diftitox as Novel Targeted Therapy for Lymphoid Malignancies

Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

2001 • 612 citations

The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant Lymphocytes

1986 • 460 citations

Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors.

1987 • 252 citations

Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein

1987 • 236 citations

Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein.

1988 • 220 citations

Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes

1985 • 193 citations

Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells.

1990 • 191 citations

Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2

1998 • 188 citations

Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes.

1987 • 176 citations

Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor

1992 • 159 citations

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

2004 • 143 citations

Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

2006 • 135 citations

Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor

1992 • 121 citations

Biological Correlates of Acute Hypersensitivity Events with DAB389IL-2 (Denileukin Diftitox, ONTAK®) in Cutaneous T-Cell Lymphoma: Decreased Frequency and Severity with Steroid Premedication

2001 • 120 citations

Interleukin 2 receptor‐targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin‐related interleukin 2 fusion protein into cells

1990 • 117 citations

A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma

2005 • 110 citations

CD25 Expression Is Correlated with Histological Grade and Response to Denileukin Diftitox in Cutaneous T-Cell Lymphoma

2006 • 100 citations

Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

2004 • 96 citations

Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox

2002 • 87 citations

Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers.

1993 • 87 citations

Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study

1994 • 81 citations

A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.

2003 • 70 citations

DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma

1998 • 68 citations

Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease

2005 • 60 citations

Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy

1994 • 59 citations

Treatment of Refractory Peripheral T-cell Lymphoma with Denileukin Diftitox (ONTAK ® )

2002 • 58 citations

Selective Elimination of HIV-1-Infected Cells with an Interleukin-2 Receptor-Specific Cytotoxin

1991 • 55 citations

Interleukin 2 receptor targeted fusion toxin (DAB₄₈₆‐IL‐2) treatment blocks diabetogenic autoimmunity in non‐obese diabetic mice

1992 • 41 citations

Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene

2002 • 37 citations

Phase I Trial of the Diphtheria Toxin/Interleukin-2 Fusion Protein DAB₄₈₆IL-2: Efficacy in Mycosis Fungoides and Other Non-Hodgkin's Lymphomas

1993 • 36 citations

Denileukin Diftitox and Hyper-CVAD in the Treatment Human T-Cell Lymphotropic Virus 1–Associated Adult T-Cell Leukemia/Lymphoma

2003 • 31 citations

Suppression of immune responses to acetylcholine receptor by interleukin 2-fusion toxin: in vivo and in vitro studies

1991 • 16 citations

Concomitant administration of hapten and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones.

1990 • 15 citations

The Interleukin‐2 Fusion Protein, DAB₃₈₉IL‐2, Inhibits the Development of Infectious Virus in Human Immunodeficiency Virus Type 1‐Infected Human Peripheral Blood Mononuclear Cells

1997 • 15 citations

INHIBITION OF HIV-1 RNA PRODUCTION BY THE DIPHTHERIA TOXIN-RELATED IL-2 FUSION PROTEINS DAB486IL-2 AND DAB389IL-2

1992 • 15 citations

A complete and durable response to denileukin diftitox in a patient with mycosis fungoides

2003 • 13 citations

Suppression of Immunopathology in Schistosomiasis by Interleukin-2-Targeted Fusion Toxin, DAB389IL-2 I. Studies ofin Vitroandin VivoEfficacy

1995 • 11 citations

Remission of Follicular Non-Hodgkin's Lymphoma with Denileukin Diftitox (ONTAK ® ) After Progression During Rituximab, CHOP and Fludarabine Therapy

2003 • 8 citations

DAB486-IL-2 (IL-2-toxin) in combination with low-dose RS-61443 (mycophenolate mofetil) prolongs murine thyroid allograft survival.

1993 • 3 citations

Intoxication of high affinity IL-2 receptor positive thymocytes blocks early stages of T cell maturation

1992 • 3 citations

Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma.

2005 • 2 citations

Prolongation of murine thyroid allografts by interleukin 2 (DAB486)-toxin and RS-61443

1992 • 1 citations

Prolongation of murine thyroid allografts by interleukin 2 (DAB486)-toxin and RS-

1992 • 1 citations